LE WE PMID CA
Antisense181Antisense

Antibiotics (BASKET)

Antisense

Duchenne s muscular dystrophy

Locked nucleic acid

RNA (MicroRNA)

RNA (non coding)

RNA (Splicing)

Splicing

2004  
1
2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents.
[15056846] Biol Pharm Bull 27(4): 453-6 (2004)
1998  
2
Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes.
[9841677] Microbiol Mol Biol Rev 62(4): 1415-34 (1998)
1998  
3
Gene therapy for infectious diseases.
[9457428] Clin Microbiol Rev 11(1): 42-56 (1998)
2009  
4
Improved applications of the tetracycline-regulated gene depletion system.
[20103842] Biosci Trends 3(5): 161-7 (2009)
2007  
5
Regulating gene expression with light-activated oligonucleotides.
[17245489] Mol Biosyst 3(2): 100-10 (2007)
2008  
6
Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.
[19787090] Gene Regul Syst Bio 2(): 275-95 (2008)
2008  
7
DNAzyme technology and cancer therapy: cleave and let die.
[18281510] Mol Cancer Ther 7(2): 243-51 (2008)
2002  
8
Antisense oligonucleotides: basic concepts and mechanisms.
[12489851] Mol Cancer Ther 1(5): 347-55 (2002)
1988  
9
Oligodeoxynucleotides as inhibitors of gene expression: a review.
[3282648] Cancer Res 48(10): 2659-68 (1988)
2009  
10
A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground.
[19139297] Arch Neurol 66(1): 32-8 (2009)
2001  
11
Triplex forming oligonucleotides: sequence-specific tools for gene targeting.
[11673407] Hum Mol Genet 10(20): 2243-51 (2001)
2000  
12
Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.
[11086018] J Clin Invest 106(10): 1189-95 (2000)
2000  
13
Therapeutic applications of transcription factor decoy oligonucleotides.
[11067859] J Clin Invest 106(9): 1071-5 (2000)
1997  
14
Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.
[9252130] Hepatology 26(2): 251-5 (1997)
1996  
15
A hitchhiker's guide to antisense and nonantisense biochemical pathways.
[8938189] Hepatology 24(6): 1517-29 (1996)
1999  
16
Antisense and nuclear medicine.
[10210231] J Nucl Med 40(4): 693-703 (1999)
2001  
17
Prospects of chimeric RNA-DNA oligonucleotides in gene therapy.
[11702006] J Biomed Sci 8(6): 439-45 (2001)
2003  
18
Design and applications of modified oligonucleotides.
[12563516] Braz J Med Biol Res 36(2): 143-51 (2003)
2004  
19
Progress in the development of nucleic acid therapeutics for cancer.
[14726654] Cancer Biol Ther 3(1): 4-12 (2004)
2011  
20
Oligonucleotides decoy to NF-kappaB: becoming a reality?
[21878187] Discov Med 12(63): 97-105 (2011)
2003  
21
Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.
[12925686] J Clin Invest 112(4): 481-6 (2003)
2003  
22
Antisense technologies. Improvement through novel chemical modifications.
[12694176] Eur J Biochem 270(8): 1628-44 (2003)
2009  
23
Locked nucleic acid as a novel class of therapeutic agents.
[19458498] RNA Biol 6(3): 321-3 (2009)
2009  
24
Regulatory roles of natural antisense transcripts.
[19638999] Nat Rev Mol Cell Biol 10(9): 637-43 (2009)
2010  
25
Progress in therapeutic antisense applications for neuromuscular disorders.
[19809477] Eur J Hum Genet 18(2): 146-53 (2010)
2010  
26
Crystallographic studies of chemically modified nucleic acids: a backward glance.
[20087997] Chem Biodivers 7(1): 60-89 (2010)
2011  
27
Deoxyribozymes: new therapeutics to treat central nervous system disorders.
[21977013] Front Mol Neurosci 4(-): 25 (2011)
2009  
28
Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
[18813282] Mol Ther 17(3): 548-53 (2009)
2010  
29
MicroRNA sponges: progress and possibilities.
[20855538] RNA 16(11): 2043-50 (2010)
2007  
30
Modulating the expression of disease genes with RNA-based therapy.
[17604456] PLoS Genet 3(6): e109 (2007)
2002  
31
Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide.
[11971990] Mutagenesis 17(3): 201-9 (2002)
2009  
32
Progress toward therapy with antisense-mediated splicing modulation.
[19330717] Curr Opin Mol Ther 11(2): 116-23 (2009)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Antisense

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia